Drug Detail

Information about DCC-3116

Generic Name
IND	DCC-3116
Brand Name (US)
Manufacturer	Deciphera
Drug Type	ULK1/2 Inhibitor
Delivery	Oral
Approval Status	Phase 1/2
Indications
Overall Strategy	Inhibit Adaptive Stress Response (ASR)Pathway signalling
Strategy	Block ASR autophagy activation
Drug Category	ULK1/2 inhibitor

DCC-3116 is a selective, potent, first-in-class,
investigational inhibitor of ULK1/2 in clinical
development in combination with targeted therapies that
activate the autophagic ASR escape pathway1,2

Links
	AACR 4/18/2023 DCC-3116, a first-in-class selective ULK1/2 inhibitor of autophagy, in combination with the KIT inhibitor ripretinib induces complete regressions in GIST preclinical models

	AACR 4/18/2023 Presentation of New Preclinical Data Highlighting SDiscovery Research Programs at AACR Annual Meeting 2023

	IJ of Molecular Sciences Jan. 4, 2023 Small Molecule Inhibitors for Unc-51-like Autophagy-Activating Kinase Targeting Autophagy in Cancer

	IJ of Molecular Sciences Nov. 17, 2021 Clinical Translation of Combined MAPK and Autophagy Inhibition in RAS Mutant Cancer

Trials of this drug
Trial results

Search for this drug/combination in:

ClinicalTrials.gov